This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

An Open Label Phase I Dose Escalation Study of E7080 Administered to Patients With Solid Tumors

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Eisai Inc.
ClinicalTrials.gov Identifier:
NCT00280397
First received: January 20, 2006
Last updated: August 29, 2016
Last verified: August 2016
Results First Received: February 21, 2015  
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Cancer: Solid Tumors
Intervention: Drug: E7080

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
E7080 Group E7080 is administered orally twice a day for 2 weeks to patients with solid tumors that are resistant to approved conventional therapies or for which no appropriate treatment is available.

Participant Flow:   Overall Study
    E7080 Group
STARTED   27 
COMPLETED   26 
NOT COMPLETED   1 
Adverse Event                1 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
E7080 Group E7080 is administered orally twice a day for 2 weeks to patients with solid tumors that are resistant to approved conventional therapies or for which no appropriate treatment is available.

Baseline Measures
   E7080 Group 
Overall Participants Analyzed 
[Units: Participants]
 27 
Age 
[Units: Years]
Mean (Standard Deviation)
 50.7  (11.1) 
Gender, Customized 
[Units: Participants]
 
Male   10 
Female   17 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Maximum Tolerable Dose (MTD) of E7080 Repeatedly Administered Twice a Day   [ Time Frame: up to 4 weeks ]

2.  Primary:   DLT of E7080 Repeatedly Administered Twice a Day   [ Time Frame: up to 4 weeks ]

3.  Secondary:   Number of Participants With Adverse Events / Serious Adverse Events   [ Time Frame: Until tumor progression, unacceptable toxicity, or withdrawal due to other reasons. ]

4.  Secondary:   To Elucidate the Pharmacokinetic Profile of E7080   [ Time Frame: Every 3 weeks ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  

5.  Secondary:   Determine the Clinical Dose for Phase II Study Based on Safety and Pharmacokinetic Profile   [ Time Frame: Every 3 weeks ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  

6.  Secondary:   Evaluate the Anti-tumor Activity of E7080   [ Time Frame: Every 3 weeks ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  

7.  Secondary:   To Make Exploratory Analyses of Pharmacodynamic Markers   [ Time Frame: Every 3 weeks ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Akihiko Tsuruoka
Organization: Eisai Co., Ltd.
phone: +81-3-3817-5252 ext 5252


Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Eisai Inc.
ClinicalTrials.gov Identifier: NCT00280397     History of Changes
Other Study ID Numbers: E7080-J081-103
Study First Received: January 20, 2006
Results First Received: February 21, 2015
Last Updated: August 29, 2016